Ozempic (Semaglutide)

Čo je Ozempic (Semaglutide)?

Ozempic (semaglutide) is a once-weekly injectable prescription medicine that belongs to the GLP-1 receptor agonist class. It is approved by the European Medicines Agency (EMA) for the treatment of type 2 diabetes in adults and is also used off-label by doctors for weight management in eligible patients.

Ako funguje Ozempic (Semaglutide)?

Ozempic works by mimicking the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone released by the gut after eating. When semaglutide binds to GLP-1 receptors throughout the body, it triggers several clinically significant responses:

• Appetite suppression: Signals in the brain’s hypothalamus reduce hunger and increase feelings of fullness (satiety), leading to reduced caloric intake.
• Slowed gastric emptying: Food moves more slowly from the stomach to the small intestine, prolonging the sensation of fullness after meals.
• Blood glucose regulation: Semaglutide stimulates insulin release from the pancreas in response to food and suppresses the release of glucagon, a hormone that raises blood sugar levels.
• Cardiovascular effects: Clinical data published by the EMA indicates that semaglutide reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Because the GLP-1 receptors targeted by semaglutide are distributed across multiple organ systems — including the brain, gut, heart, and pancreas — Ozempic’s effects extend beyond blood sugar control to include meaningful body weight reduction.

Pre koho je určený/á Ozempic (Semaglutide)?

Ozempic is indicated for adults with type 2 diabetes mellitus when diet and exercise alone are insufficient to achieve adequate glycaemic control. In clinical practice, independent doctors may also consider prescribing semaglutide off-label for weight management in adults who meet specific eligibility criteria, typically including:

• A body mass index (BMI) of 30 or above, or
• A BMI of 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea

Ozempic is not appropriate for everyone. It is not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC), people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those who are pregnant or planning to become pregnant. A full medical assessment by a qualified doctor is required before any prescription can be issued.

Dávkovanie

Ozempic is administered once weekly by subcutaneous injection (under the skin of the abdomen, thigh, or upper arm). The standard titration schedule, as per EMA-approved prescribing guidance, is:

Phase	Dose	Duration
Starting dose	0.25 mg once weekly	4 weeks
Maintenance step 1	0.5 mg once weekly	At least 4 weeks
Maintenance step 2 (if needed)	1 mg once weekly	Ongoing or as directed
Maximum dose	2 mg once weekly	As clinically indicated

The starting dose of 0.25 mg is used to minimise gastrointestinal side effects during the initial weeks of treatment. Dose escalation should only occur under a doctor’s supervision. Patients should not adjust their dose without consulting their prescribing doctor.

Ozempic is available as a pre-filled injection pen. Injections can be given at any time of day, with or without food.

Vedľajšie účinky

As with all medicines, Ozempic may cause side effects. Not all patients experience them, and many resolve as the body adapts to the medication.

Časté vedľajšie účinky (môžu postihnúť viac ako 1 z 10 osôb)

• Nausea
• Diarrhoea
• Vomiting
• Constipation
• Abdominal pain or discomfort

These gastrointestinal effects are most common during the first weeks of treatment and typically become less severe over time. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated may help manage them.

Menej časté, ale závažné vedľajšie účinky

• Pancreatitis: Persistent severe abdominal pain that may radiate to the back. Stop treatment and seek immediate medical attention if this occurs.
• Gallbladder problems: Including gallstones (cholelithiasis) and cholecystitis. Report any upper-right abdominal pain, fever, or jaundice to a doctor promptly.
• Diabetic retinopathy complications: Reported in patients with pre-existing diabetic eye disease. Regular eye examinations are recommended.
• Hypoglycaemia: Risk is increased when semaglutide is used in combination with insulin or sulphonylureas.
• Acute kidney injury: Typically secondary to dehydration caused by gastrointestinal side effects.
• Allergic reactions: Serious allergic reactions, including anaphylaxis, have been reported rarely.

This is not a complete list of side effects. Refer to the EMA-approved product information for full prescribing details.

Ozempic (Semaglutide) vs alternatívy

Several GLP-1 receptor agonists and weight management medicines are available in Europe. The table below provides a factual comparison for informational purposes only. A doctor must assess which, if any, of these medicines is appropriate for an individual patient.

Medicine	Active Ingredient	Form	Typical Dose	Approved Indication
Ozempic	Semaglutide	Weekly injection	0.5–2 mg/week	Type 2 diabetes (EU)
Wegovy	Semaglutide	Weekly injection	Up to 2.4 mg/week	Weight management (EU)
Saxenda	Liraglutide	Daily injection	Up to 3 mg/day	Weight management (EU)

Hlavné rozdiely:

• Ozempic vs Wegovy: Both contain semaglutide. Ozempic carries an EMA approval for type 2 diabetes at doses up to 2 mg. Wegovy is approved specifically for chronic weight management at a higher maximum dose of 2.4 mg. Clinical evidence supports greater average weight loss at the higher Wegovy dose.
• Ozempic vs Saxenda: Saxenda contains liraglutide, a different GLP-1 agonist that requires daily (rather than weekly) injections. Clinical head-to-head data indicates semaglutide (Ozempic/Wegovy) produces greater mean weight loss than liraglutide (Saxenda) over comparable treatment periods, per published clinical trial data referenced by the EMA.

Ako získať Ozempic (Semaglutide) online v Európe

Ozempic je liek viazaný na lekársky predpis vo všetkých členských štátoch EÚ. Nemožno ho legálne vydať bez platného predpisu od licencovaného lekára.

Prescrivia pôsobí ako technologický sprostredkovateľ: nepredpisujeme lieky, nezamestnávame lekárov ani nepredávame lieky. Naša platforma spája pacientov s nezávislými lekármi registrovanými v EÚ, ktorí môžu vykonávať dôverné online zdravotné posúdenia.

Postup je nasledovný:

1. Vyplňte zdravotný dotazník: Answer a structured set of health questions designed to capture relevant medical history, current medications, and treatment goals. This assessment is reviewed by an independent doctor.
2. Posúdenie lekárom: An independent EU-registered doctor reviews your assessment. If semaglutide is clinically appropriate for you, they may issue a prescription. If it is not appropriate, the doctor will explain why.
3. Predpis a vybavenie: If a prescription is issued, it is sent to a licensed EU pharmacy partner. The pharmacy dispenses and ships the medicine directly to you.

Dôležité: Prescrivia nezaručuje, že bude predpis vystavený. Všetky rozhodnutia o predpisovaní vykonávajú nezávisle kvalifikovaní odborní lekári na základe Vašich individuálnych klinických okolností.

Dôležité bezpečnostné informácie

Nepoužívajte Ozempic (Semaglutide) ak:

• Have a personal or family history of medullary thyroid carcinoma (MTC)
• Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Are allergic to semaglutide or any other ingredient in Ozempic
• Are pregnant, planning to become pregnant, or breastfeeding

Informujte svojho lekára pred začatím užívania Ozempic (Semaglutide) ak máte:

• A history of pancreatitis
• Diabetic retinopathy
• Kidney disease
• Liver disease
• Gallbladder disease
• A history of eating disorders

Liekové interakcie: Ozempic may interact with other medications, particularly insulin and sulphonylureas (risk of hypoglycaemia), and oral contraceptives (potential reduced absorption due to delayed gastric emptying). Always disclose all current medications to your doctor during the assessment.

Ozempic is not a substitute for lifestyle changes. Dietary modification and regular physical activity remain important components of any weight management or diabetes treatment plan.

Zdroje

Lekárske informácie na tejto stránke vychádzajú z nasledujúcich zdrojov:

• European Medicines Agency (EMA). Ozempic (semaglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
• European Medicines Agency (EMA). Assessment report: Ozempic. EMEA/H/C/004174.
• World Health Organization (WHO). Obesity and overweight — Fact sheet. who.int
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

Tento obsah je pravidelne prehodnocovaný s ohľadom na aktualizované klinické usmernenia. Je poskytovaný len na informačné účely a nepredstavuje lekárske poradenstvo. Vždy sa poraďte s kvalifikovaným zdravotníckym pracovníkom o rade týkajúcej sa Vašich individuálnych zdravotných okolností.